ARCHIVES

51% Control Rate Achieved In Phase II Trial of Elderly Patients

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

NIH Should Review CRADA Pricing, Wyden Write to Shalala

February 5, 1993

FTE Shortage Hurting Cancer and AIDS Research, Advisors Told; NCI Seeks Major Share Of New Slots

October 14, 1988

In Brief: FDA’s Burlington Moves to Wyeth-Ayerst; NAS Award to Beckman; Genetics Online

February 5, 1999

In Brief: Howard Skipper Retires; Oglesby To Head SRI; John Montgomery Named Kettering-Meyer Director

December 19, 1980

Hope for FDA authority over tobacco products dies in Congress.

October 15, 2004

Pooled Analysis of Two LUX-Lung Trials Shows Prolonged Survival with Afatinib

June 27, 2014